Leading Edge Genomic Services & Solutions

Novogene Establishes its First European Genomic Sequencing Center in Cambridge, UK

Cambridge, UK – May 21, 2018 – Novogene, a leading global provider of genomics services and solutions, today announced its first genomic sequencing center in Europe. The Novogene UK Genomic Sequencing Center will be established at the Babraham Research Campus in Cambridge in the United Kingdom. The center will provide an important base for Novogene to serve its European customers and contribute to human health across Europe.

The Novogene UK Genomic Sequencing Center will be equipped with a full automation system and the latest Illumina NovaSeq and supercomputing platforms. Establishing this facility will enable Novogene to provide cutting-edge next-generation sequencing and bioinformatics services and solutions to scientists at European universities, research institutes, pharmaceutical companies, and biotechnology companies.

“We are proud to set up our first European laboratory at the Babraham Research Campus,” said Dr. Ruiqiang Li, Founder and CEO of Novogene. “Our UK lab is our first step towards addressing the increasing demand from our European customers and will help us contribute to advancing human health, environmental protection, and plant and animal breeding in the United Kingdom and the whole of Europe.”

Derek Jones, CEO of Babraham Bioscience Technologies, which is responsible for the management and development of the Babraham Research Campus added: “I am extremely pleased to welcome Novogene to the Babraham Research Campus. The role of genomics is rapidly evolving and the Cambridge Cluster has become a hub for innovation in this area, attracting leader organizations, like Novogene, to locate here. Close proximity to academic and commercial collaborateors – both on campus and within the wider cluster – is hugely beneficial to the organizations based here and results in innovative and ground-breaking research that will ultimately benefit us all.”

About Babraham Research Campus
Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus.

The Babraham Research Campus is distinct in its co-location of 60 bioscience companies with the Babraham Institute, a world-renowned research organization which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC).

The aim of the campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organizations. The campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute. For more information please visit: www.babraham.com.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit http://en.novogene.com/.

Contact:
Tingting Zhou
General Manager
Novogene Europe
zhoutingting@novogene.com

The Babraham Research Campus
Derek Jones
CEO
Babraham Bioscience Technologies Ltd
derek.jones@babraham.co.uk

Novogene Receives CLIA Certification for its Clinical Laboratory in Sacramento, California

Sacramento, California – May 1, 2018 – Novogene, a leading global provider of genomic services and solutions, announced that it successfully obtained CLIA certification for its clinical laboratory on March 27, 2018.

The Clinical Laboratory Improvement Amendments (CLIA) are the US federal regulatory standards that apply to US facilities that test human specimens for diagnosis, prevention or treatment of disease or other health assessment. CLIA regulations require clinical laboratories to be certified by their state and the Centers for Medicare and Medicaid Services (CMS) before they can accept human samples for clinical testing. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) support the regulations of CLIA and play unique roles in assuring quality laboratory testing. An important objective of the CLIA is to ensure the accuracy, reliability and timeliness of clinical test results.

The process of CLIA certification includes inspections of the following: specimen collection, sample transportation, sample preparation and storage, laboratory platforms, assay validation, instrument and reagent calibration, quality assessment and proficiency testing, laboratory biosafety inspection, and onsite audit of laboratory environment, staff, and management system. Novogene’s Sacramento laboratory has passed all the above inspections and demonstrated its assay’s reliable performance.

The CMS also evaluates the performance characteristics of a laboratory’s bioinformatics analysis pipeline. Novogene’s bioinformatics pipeline integrates public data with its in-house database. With its comprehensive database and bioinformatics pipeline, Novogene is able to deliver clinical-grade genomic testing.

According to Dr. David Jiang, General Manager of Clinical and Consumer Genomics at Novogene, “CLIA certification is an important milestone for Novogene, allowing us to provide genomic solutions not only for scientific research, but also for clinical testing. We are excited to offer our clinical partners high-quality sequencing services at low cost with fast turn-around time. Our goal is to democratize sequencing in the clinical space.”

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit http://en.novogene.com.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

The University Medical Center Groningen and Novogene Announce the Start of the 10K Metagenome Project

Groningen, Netherlands and Beijing, China – October 31, 2017 — A research group led by Professor Cisca Wijmenga from the University Medical Center Groningen (UMCG) and Novogene, a leading global provider of genomic services and solutions, today announced a partnership to start the 10K Metagenome Project to further study population-based metagenomics.

The 10K Metagenome Project is initiated by Professor Cisca Wijmenga, Professor Rinse Weersma, Associate Professor Jingyuan Fu, and Associate Professor Alexandra Zhernakova from UMCG. This project aims to analyze 10,000 gut microbiomes from a large, deeply phenotyped population-based cohort in the Netherlands by using next-generation sequencing to study interactions between the microbiome and exogenous and intrinsic host factors. This follows a successful proof of concept study that was published last year in Science (Zhernakova et al., 2016). As part of the partnership, Novogene will provide next-generation sequencing for stool samples collected by UMCG and deliver high-quality data for each metagenome.

“Metagenomic shotgun sequencing allows us to discover intrinsic and exogenous factors that correlate with shifts in the microbiome composition and functionality,” said Professor Cisca Wijmenga, Spinoza Prize winner at UMCG. “Combined with the 8000 phenotypes present in the biobank, this rich dataset will enhance our understanding of which strains and pathways prevent or cause disease, a first step in translational research”.

“By leveraging the largest sequencing capacity in the world as well as our rich experience with next-generation sequencing technology, Novogene is taking an active role in accelerating genomic studies from all over the world,” said Ms. Tingting Zhou, General Manager of Novogene Europe. “It’s a great honor to partner with distinguished scholars from UMCG on the 10K Metagenome Project. This unprecedented study will shed more light on gut metagenomics, and therefore provide a better understanding of human health. We are proud to be part of it.”

About UMCG
The University Medical Center Groningen (UMCG) was established in 2005 as a joint activity of the University of Groningen and the Academic Hospital Groningen (AZG). At present, the UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 12,000 employees provide patient care, are involved in medical education and performing cutting-edge scientific research, and are focused on “healthy and active aging”.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit http://en.novogene.com/.

Contact:

Professor Cisca Wijmenga, UMCG
C.Wijmenga@umcg.nl

Professor Rinse Weersma, UMCG
r.k.weersma@umcg.nl

Weiyan Peng
Business Development Director
Novogene Europe
pengweiyan@novogene.com

Novogene prepares to enter the proteomics service market with the addition of five Thermo Scientific™ Q Exactive™ HF-X Mass Spectrometers

San Diego and Beijing, October 5, 2017 — Novogene, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, recently announced the stationing of five Thermo Scientific™ Q Exactive™ HF-X Hybrid Quadrupole-Orbitrap™ Mass Spectrometers in its Tianjin laboratory. With this addition, the company will be able to begin offering proteomic services. Novogene is committed to building the world’s most advanced biological mass spectrometry center to provide customers with comprehensive and in-depth multi-omics solutions.

The Q Exactive™ HF-X Mass Spectrometer uses a high-capacity transfer tube for maximum ion loading, an electrodynamic ion funnel that accommodates and transmits ions over a broader mass range, and a high-field Thermo Scientific™ Orbitrap™ mass analyzer. The platform significantly improves the scanning speed to an unprecedented 40Hz, the sensitivity by up to 10 times, as well as the quantitative reproducibility and sample throughput of protein detection. These features make the Q Exactive™ HF-X better-suited for the in-depth study of proteomics of complex biological samples.

As a world-leading sequencing services provider, Novogene has shown unsurpassed strength and capacity in genomic services and solutions since its founding in 2011. With the addition of five high-resolution Q Exactive™ HF-X Mass Spectrometers, Novogene has marked its transition from a genetic sequencing service company to a full service, multi-omics solution provider to better serve its customers worldwide and to enhance the quality of scientific research and precision medicine.

“Novogene has been focusing on applying high-throughput sequencing technologies in the field of scientific research over the years, and has become the world’s largest next-generation and SMRT sequencing center,” said Dr. Zhi Jiang, President of Novogene. “Proteomics is closer to the dynamic changes in life activities and phenotypic variation. With the continuous development of the mass spectrometry technology, we have seen a growing demand for multi-omics research. We have had a long-term collaboration in genomic sequencing and molecular diagnostics with Thermo Fisher already and we look forward to this in-depth cooperation to jointly promote the development of proteomics in the life sciences research with Thermo Fisher.”

Novogene’s services cover scientific research, cancer gene detection and genetic testing areas. With the largest sequencing capacity and gene interpretation capabilities worldwide, Novogene has provided genomic sequencing and bioinformatics data analysis services to global customers in research universities, research institutes, hospitals, pharmaceutical R&D companies and agricultural companies. Novogene is committed to promoting the rapid development and application of proteomics in the scientific research services area using the advanced high-resolution mass spectrometry platforms and solutions from Thermo Fisher.

Contacts:

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

PacBio Announces New Agreement with Novogene to Purchase Ten Sequel Systems – Increases Novogene’s Capacity to Run 20 Sequel Systems at a Time

MENLO PARK, Calif., and SAN DIEGO, Calif., August 2, 2017 — Pacific Biosciences of California, Inc. (Nasdaq:PACB) and Novogene Corporation today announced a new agreement by Novogene to purchase 10 Sequel® Systems, giving the DNA sequencing service provider the capacity to run up to 20 Sequel Systems at a time.

Novogene, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, is the largest user of PacBio’s Sequel Systems in the world. The service provider has ramped its use of the system dramatically since earlier in the year when it acquired acesss to the first 10 Sequel Systems through the Nanjing Yangzi State-Owned Investment Group in China.

The Sequel System, based on PacBio’s unique Single Molecule, Real-Time (SMRT®) technology, provides an unmatched depth of genetic information through exceptionally long sequencing reads, uniform coverage, and the highest consensus accuracy available today. The technology allows scientists to go beyond fragmented draft genomes and generate the most comprehensive de novo assemblies.

“The overwhelming demand for SMRT Sequencing in the few months since we began running the Sequel Systems has required us to double our capacity in a short amount of time,” said Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “Some of the large projects we have planned include building a database of structural variants in 1,000 Chinese individuals as part of the Chinese precision medicine initiative. In addition, we have partnered with the Global Ant Genomics Alliance to sequence 300 different species of ants to provide a comprehensive look at genomic diversity in ant genera.”

Michael Hunkapiller, Ph.D., Chairman and CEO of PacBio added: “Novogene has very quickly become the largest user of our Sequel platform, and is now operating the largest SMRT Sequencing service center in the world. We are delighted that they have successfully ramped up their utilization of the systems so quickly, and that high demand for SMRT Sequencing services in China has led them to already increase their capacity.”

About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to product orders, future uses, quality or performance of, or benefits of using, products or technologies, the expected benefits of the company’s agreement with Novogene, the suitability of the company’s products for particular markets or applications and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

For PacBio:
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com

Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

For Novogene:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

The Global Ant Genomics Alliance Announces Partnership With Novogene To Advance The Genomic Study Of Ants Around The World

July 18, 2017, Copenhagen, Denmark and Beijing, China –– The Global Ant Genomics Alliance (GAGA; http://antgenomics.dk/), an international collaboration of researchers from a variety of fields and institutions from across the globe, is partnering with Novogene Co., LTD, a leading global provider of genomic services and solutions, to make a significant leap forward in understanding the genomics of ants.

The partnership aims to obtain around 300 genomes, covering all ant genera across the world, to facilitate reconstruction of the evolutionary history and ecological resilience of this important social insect family. Under the partnership Novogene will provide PacBio sequencing for the ant species collected by the GAGA consortium and deliver high quality long-reads data, with up to 50x coverage generating 15 gigabases of long-read data for each ant genome.

“PacBio sequencing technology will allow almost gap-less genome assemblies that should make sure that ant genomes generated under GAGA will meet future quality standards of journals and repositories,” said Guojie Zhang, professor at the University of Copenhagen and head of the GAGA consortium. “The technology also requires only small amounts of DNA, significantly alleviating the biomass constraints for sampling material and enabling genome sequencing for almost all rare and small ants.”

“We are pleased to be partnering with The Global Ant Genomics Alliance on this important research endeavor,” said Dr. Ruiqiang Li, Founder, Chairman, and CEO of Novogene. “By applying our PacBio sequencing capabilities to the project we look forward to generating a robust database on the ant genome and helping advance the knowledge and understanding of this diverse species.”

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the World. Novogene pursues scientific excellence, strong commitment to customer service, and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top-tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit http://en.novogene.com/.

About The Global Ant Genomics Alliance
The Global Ant Genome Project is a growing international collaboration of researchers from a variety of fields and institutions across the world. This global project on ant genomics will provide a comprehensive dataset of the genomic diversity of the world’s ant genera. Based on the comparative analysis of these data, we will be able to understand the global trends of ant evolution and narrow down the genetic features that have been particularly relevant for the diversification and astonishing evolutionary success of ants. Researchers are interested in joining the consortium
can submit their research interest via http://antgenomics.dk/call-for-gaga-projects-and-subprojects/. For more information, click here.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Novogene Will Use Pacific Biosciences SMRT Technology to Build Novo-Disease SV Genomes Database

–First database of long-read whole genome sequencing data–

San Diego, July 18, 2017 — Novogene announced today it plans to use Pacific Biosciences SMRT® technology to build a comprehensive Chinese genome database, Novo-Disease SV Genomes. The database will consist of long-read sequencing data of 1000 Chinese genomes from a variety of disease types. As the first ever database of long-read human whole genome sequencing information, Novo-Disease SV Genomes will be a breakthrough step in the understanding of the human genome and in the field of precision medicine.

As a pioneer in the genomics field, Novogene has previously constructed the Novo-Zhonghua Genomes database, a population-specific genome database that consists of whole genome sequencing data on 2,500 normal Chinese genomes. The Novo-Zhonghua Genomes database reveals a large amount of SNPs and InDels that can be used for disease-specific variant annotation.

Databases such as Novo-Zhonghua Genomes, constructed with a large amount of genome sequencing data, lay the foundation for precision medicine. However, a genome database consisting of short-read sequencing data alone often misses the information on most structural variants (SVs), the changes in the chromosomal structure that can be linked to disease susceptibility.

Pacific Biosciences’ Single Molecule, Real-Time (SMRT) sequencing technology has the advantage of uniform coverage across all genomes. Whole genome sequencing with PacBio Systems helps provide complete and accurate views of all types of genomic variation, revealing SNPs/SNVs, structural variants, mobile elements, haplotypes, epigenetics, and variants in low-complexity regions. Furthermore, the isoform sequencing (Iso-Seq®) method with the Sequel System generates full-length cDNA sequences, which can be used to profile the full complexity of the human transcriptome and discover novel genes, isoforms, and gene fusion events.

“By applying PacBio’s SMRT technology to the construction of our Novo-Disease SV Genomes database, we will be able to apply long-read sequencing that can detect disease variants often missed by short-read sequencing,” stated Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “This more revealing and informative database should greatly improve our understanding of disease mechanisms and contribute to the development of novel diagnostic and therapeutic approaches.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene pursues scientific excellence, strong commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/

Contacts:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

Novogene and Pacific Biosciences to Jointly Develop and Co-Market Novel Applications Based on Sequel Platform

San Diego and Menlo Park, CA, July 18, 2017 — Novogene, a leading global provider of genomic services and solutions, and Pacific Biosciences of California, Inc. (NASDAQ:PACB), the leader in long-read sequencing, have agreed to jointly develop and promote novel applications based on the PacBio® Sequel® System. New applications developed under this agreement are expected to focus on basic and translational research in the field of precision medicine, including methods for sample processing, workflow automation, algorithm development, and database construction.

Sequel Systems are based on Single Molecule, Real-Time (SMRT®) technology, which has the advantage of uniform coverage across all genome regions, including palindromes and low-diversity regions of the genome. Genome sequencing with PacBio Systems helps provide more complete and accurate views of all types of genomic variation, revealing SNPs/SNVs, structural variants, mobile elements, haplotypes, epigenetics, and variants in low-complexity regions. Furthermore, the isoform sequencing (Iso-Seq®) method with the Sequel System generates full-length cDNA sequences, which can be used to profile the full complexity of the human transcriptome and discover novel genes, isoforms, and gene fusion events.

With the ability to run up to 10 PacBio Sequel Systems, Novogene operates in a facility that has the largest capacity for SMRT Sequencing in a single location. As a leading genomic service provider with a comprehensive portfolio of service products, Novogene has extensive expertise in developing and marketing high-quality end-to-end service solutions, from sample preparation to data analysis and interpretation, for a variety of applications in diverse research and clinical fields.

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene pursues scientific excellence, strong commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/

About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality, performance or advantages of, or benefits of using, products or technologies, future development or promotional efforts, the expected benefits of the company’s collaboration with Novogene, the suitability of the company’s products for particular markets or applications and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contacts:
For Novogene:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

For PacBio:
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com

Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

Novogene Adds 25 Illumina NovaSeq Sequencers

April 3, 2017, San Diego and Beijing — Novogene Corporation, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, today announced the order of 25 Illumina NovaSeq 6000 sequencers. Five of the sequencers will be located in the U.S. In addition, Novogene will operate the 20 units purchased by Nanjing Yangzi State Owned Investment Group in China. With the addition of these new NovaSeq sequencers to its existing array of 30 Illumina HiSeq X and 10 PacBio Sequel systems, Novogene now offers the largest and most advanced sequencing capacity in the world with annual throughput of 280,000 human whole genomes.

The addition of the NovaSeq sequencers not only expands Novogene’s sequencing capacity, but also greatly reduces its sequencing cycle times. With NovaSeq, Novogene will be able to sequence up to 48 human whole genomes, producing 6Tb of data, per single run as short as 40 hours. To match NovaSeq’s high capacity and efficiency, Novogene also upgraded its data storage and computing power to 878T flops, total memory of 368TB, and total storage of 29PB.

Introduced by Illumina in January 2017, NovaSeq is a highly powerful sequencer designed to be scalable and flexible for virtually any genome, method, and scale of project. In human disease research, Novogene’s addition of the NovaSeq sequencing platform will enable the study of rare genetic variations with larger sample size, greater depth and faster speed, and accelerate the progress of global precision medical research.

“We were among the first to receive Illumina’s HiSeq X sequencers when they were first introduced, so we are pleased to now be among the first to adopt the new NovaSeq sequencing system,” stated Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “We look forward to bringing the benefits of this powerful new sequencing system to our customers through affordable, flexible and scalable solutions for their diverse research needs.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit http://en.novogene.com/.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com


Two NovaSeq instruments installed on-site.

Novogene NGS Medical Lab Receives CAP Accreditation

April 4, 2017, San Diego and Beijing — Novogene Corporation, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, today announced that its next-generation sequencing (NGS) medical lab in Tianjin, China has received accreditation from the College of American Pathologists (CAP). With CAP accreditation, Novogene now will be able to provide its high-quality, well-established clinical sequencing services to customers throughout the world.

The process of CAP accreditation involves a rigorous series of inspections and certifications on lab quality management systems, experimental processes, data analysis and clinical interpretation. CAP accreditation, received on March 30th, 2017, attests to Novogene Tianjin medical lab’s global comparability and competitiveness for NGS sample quality control, personnel qualification, facilities, and quality assurance.

Novogene established its clinical service division in January 2014, and has continuously developed its clinical services in China, including tumor gene detection and genetic testing services. Novogene also established a Precision Medicine Center of Excellence with Thermo Fisher Scientific in December 2016 and is one of the first China National Genetic Testing Technology Demonstration Centers.

“Our strategy is to incorporate scientific research, clinical diagnostics, and preventive medicine synergistically to drive life science research and improve human healthcare,” stated Dr. Ruiqiang Li, CEO of Novogene. “CAP accreditation represents an important milestone for our Tianjin medical center, which can now provide superior clinical services to our more than 450 hospital customers and pharmaceutical partners globally for projects of any scale, in ways that we could not before.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journals such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit http://en.novogene.com/.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com